<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HC50A238F036E4AE3A978ED87DE1B3572" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 1512 IH: Greater Access to Contraceptive Options Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-03-09</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1512</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230309">March 9, 2023</action-date><action-desc><sponsor name-id="M000194">Ms. Mace</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To allow women greater access to a wider range of self-administered contraceptives approved under the Federal Food, Drug, and Cosmetic Act.</official-title></form><legis-body id="H7886C675E0EB401F84D91889C1BE6EEA" style="OLC"><section id="HC57635F35CCE48E8B3F28D045A0B8286" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Greater Access to Contraceptive Options Act</short-title></quote>.</text></section><section id="H56C8680E0B70481E93FE33E1C0E7A491"><enum>2.</enum><header>Applications for non-prescription contraceptive methods</header><subsection id="H914CE85E251C4F2DAC1976B4826A2FEE"><enum>(a)</enum><header>Priority review of application</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services (referred to in this section as the <quote>Secretary</quote>) shall give priority review to any supplemental application submitted under section 505(b), 510(k), or 515 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)</external-xref>, 360, 360e) for a self-administered contraceptive method to be marketed without being subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/353">21 U.S.C. 353(b)(1)</external-xref>) or treated as a prescription device.</text></subsection><subsection id="HDCCFD7C645C148798AC84600A70B4E87"><enum>(b)</enum><header>Fee waiver</header><text>The Secretary shall waive the fee under section 736(a)(1) or 738(a)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h">21 U.S.C. 379h(a)(1)</external-xref>; 379j(a)(2)) (as applicable) with respect to a supplemental application that receives priority review under subsection (a).</text></subsection><subsection id="H5BE6586CF68C4662976A3D59C2D4AA9A"><enum>(c)</enum><header>Applicability</header><text>This section applies with respect to a supplemental application described in subsection (a) thatâ€”</text><paragraph id="H1D9C0EE5D9E14E2E938E275523E69349"><enum>(1)</enum><text>is submitted before the date of enactment of this Act and remains pending as of such date of enactment; or</text></paragraph><paragraph id="H7895C3AB39E048939CD1AE474BD461D6"><enum>(2)</enum><text>is submitted after such date of enactment.</text></paragraph></subsection><subsection id="HF8A5BC71996545009D78F159ABE0F438"><enum>(d)</enum><header>Self-Administered contraceptive method defined</header><text display-inline="yes-display-inline">In this Act, the term <term>self-administered contraceptive method</term> means a drug or device (as those terms are defined in section 201 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321</external-xref>)) or combination product approved for use under the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321 et seq.</external-xref>) as a method of contraception that is administered without the intervention of a health care professional, including the birth control pill, patch, vaginal ring, or injection, such as depot medroxyprogesterone acetate.</text></subsection></section></legis-body></bill> 

